(E)-2-Iodo-4-methyl-pent-2-ene | 136152-03-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 乙烯基卤化物
• 英文名称: (E)-2-Iodo-4-methyl-pent-2-ene
• 英文别名: (E)-2-iodo-4-methylpent-2-ene
• CAS: 136152-03-9
• 化学式: C₆H₁₁I
• 分子量: 210.058
• InChiKey: VGAMWXRBBUQTGX-GQCTYLIASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  甲基異丙基乙炔 在 碘 、 二异丁基氢化铝 作用下， 生成 (E)-2-Iodo-4-methyl-pent-2-ene 、 cis-3-Jod-4-methyl-2-penten
  参考文献：
  名称：

  Synthesis of an avermectin-nemadectin hybrid.

  摘要：

  The Wittig condensation of (2R,3R,4E)-2,6-dimethyl-3-trimethylsilyloxy-4-heptenyltriphenylphosphorylidene with aldehyde 1 produced the desired cis olefin 11 in 45% yield. Treatment of this intermediate with pyridinium tosylate in methanol effected spiroketalization and desilylation with hydrogen fluoride-pyridine in THF afforded the avermectin-nemadectin hybrid 2.

  DOI：

  10.1016/s0040-4039(00)79760-7

文献信息

• THIOHYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE
  申请人：Magda Darren

  公开号：US20090023798A1

  公开（公告）日：2009-01-22

  Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase. Also described herein are methods of using such HDAC inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC activity.

  本文描述了一些化合物和含有这些化合物的药物组合物，这些化合物能够抑制组蛋白去乙酰化酶的活性。本文还描述了使用这些HDAC抑制剂的方法，单独或与其他化合物联合使用，用于治疗需要抑制HDAC活性的疾病或病况。
• NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS
  申请人：Verner J. Erik

  公开号：US20080004331A1

  公开（公告）日：2008-01-03

  The present invention is directed to certain hydroxamate derivatives that are useful in the treatment of hepatitis C. These compounds are also inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed.

  本发明涉及某些羟肟酸衍生物，其在治疗丙型肝炎方面具有用途。这些化合物也是组蛋白去乙酰化酶的抑制剂，因此在治疗与组蛋白去乙酰化酶活性相关的疾病方面也具有用途。此外，还公开了制备这些化合物的药物组合物和过程。
• US7420089B2
  申请人：——

  公开号：US7420089B2

  公开（公告）日：2008-09-02